Bevacizumab對(duì)人視網(wǎng)膜色素上皮細(xì)胞纖維化相關(guān)炎癥因子表達(dá)的影響.pdf_第1頁(yè)
已閱讀1頁(yè),還剩46頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、分類號(hào):R774 密級(jí):UDC:617 學(xué)校代碼:11065碩士學(xué)位論文Bevacizumab 對(duì)人視網(wǎng)膜色素上皮細(xì)胞纖維化相關(guān)炎癥因子表達(dá)的影響對(duì)人視網(wǎng)膜色素上皮細(xì)胞纖維化相關(guān)炎癥因子表達(dá)的影響儲(chǔ)三軍指 導(dǎo) 教 師 徐海峰學(xué)科專業(yè)名稱 眼科學(xué)論文答辯日期 2015 年 5 月 22 日AbstractPurpose:To investigate the effect of anti-vascular epithelial growth

2、 factor (VEGF) agents onthe expressions of fibrosis-related inflammatory mediators under normoxic and hypoxicconditions, and to further clarify the mechanism of fibrosis after the treatment ofanti-VEGF.Methods:ARPE-19 ce

3、lls were incubated under normoxic and hypoxic conditions. For hypoxiatreatment, CoCl2 at 200μmol/L was added to the media. ARPE-19 cells were cultured anddivided into 4 groups: ①normal control group: conventional culture

4、. ②bevacizumabgroup: bevacizumab at 0.25mg/ml was added to the media. ③hypoxia group: CoCl2 at200μmol/L was added to the media. ④ hypoxia + bevacizumab group: CoCl2 at200μmol/L and bevacizumab at 0.25mg/ml were added to

5、the media. The secretion ofinterleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α were evaluated by real-timePCR and ELISA at 6 h, 12 h, 24 h and 48 h.ResultsBoth mRNA and protein levels of IL-1β, IL-6 and IL-8 i

6、n bevacizumab group werehigher than control group at 4 time points, the difference was statistically significant,while the expression of TNF-α gene and protein increased significantly only at 24h and48h (p <0.05). In

7、hypoxia conditions, bevacizumab significantly increased the secretionof IL-1β, IL-6, IL-8, and TNF-α at 6h, 12h, 24h and 48h(p <0.05). IL-1 β, IL-8, andTNF-α peaked at 24h, and IL-6 peaked at 12h after the treatment o

8、f bevacizumab underboth conditions.ConclusionsTreatment of ARPE-19 cells with bevacizumab can significantly increase thesecretion of fibrosis-related inflammatory mediators under normoxic and hypoxicconditions. Inflammat

9、ory factors may be involved in the process of fibrosis after VEGFtreatment, the up regulation expression of inflammatory factors induced by anti-VEGFdrugs may promote the fibrosis process.Keywords: bevacizumab; fibrosis;

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 眾賞文庫(kù)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論